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Abstract 
Complete tumor removal during surgery has a great impact on patient survival. To that end, the surgeon should 
detect the tumor, remove it and validate that there are no residual cancer cells left behind. Residual cells at the 
incision margin of the tissue removed during surgery are associated with tumor recurrence and poor prognosis 
for the patient. In order to remove the tumor tissue completely with minimal collateral damage to healthy 
tissue, there is a need for diagnostic tools that will differentiate between the tumor and its normal 
surroundings. 
Methods: We designed, synthesized and characterized three novel polymeric Turn-ON probes that will be 
activated at the tumor site by cysteine cathepsins that are highly expressed in multiple tumor types. Utilizing 
orthotopic breast cancer and melanoma models, which spontaneously metastasize to the brain, we studied the 
kinetics of our polymeric Turn-ON nano-probes. 
Results: To date, numerous low molecular weight cathepsin-sensitive substrates have been reported, 
however, most of them suffer from rapid clearance and reduced signal shortly after administration. Here, we 
show an improved tumor-to-background ratio upon activation of our Turn-ON probes by cathepsins. The 
signal obtained from the tumor was stable and delineated the tumor boundaries during the whole surgical 
procedure, enabling accurate resection.  
Conclusions: Our findings show that the control groups of tumor-bearing mice, which underwent either 
standard surgery under white light only or under the fluorescence guidance of the commercially-available 
imaging agents ProSense® 680 or 5-aminolevulinic acid (5-ALA), survived for less time and suffered from tumor 
recurrence earlier than the group that underwent image-guided surgery (IGS) using our Turn-ON probes. Our 
"smart" polymeric probes can potentially assist surgeons’ decision in real-time during surgery regarding the 
tumor margins needed to be removed, leading to improved patient outcome. 
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Introduction 
When cancer is diagnosed in its early stages, 
before metastatic spread, the primary treatment is 
surgical resection. The complete removal of the 









improving patient outcome. If cancer cells are 
detected in the surrounding tissue excised during 
surgery, it is considered a “positive tumor margin”, 
which is associated with poor prognosis, higher rates 
of recurrence and lower survival rates in various 
cancer types [1-8]. Maneuvering between the two 
edges of damaging healthy tissues [9] and leaving 
residual disease is the main challenge during tumor 
resection that could certainly benefit from relying on 
more than the surgeon’s naked eye. Image-guided 
surgery (IGS) has recently emerged as a 
complementary imaging technique to white light, 
supplying the surgeon an essential tool for the 
important goals mentioned above. The area of IGS has 
evolved rapidly during the last two decades, as 
reflected by the various imaging agents for different 
modalities, such as diffuse tensor imaging (DTI) and 
functional MRI (fMRI), that function as diagnostics 
before surgery to locate the tumor in relation to 
functional regions, and during surgery in order to 
assess the tumor margins [10-15]. However, these 
modalities lack the possibility of using targeted 
contrast agents to specifically visualize certain 
enzymes that are highly active at the tumor site, thus 
enabling better differentiation of cancerous from 
healthy tissue. In addition, intraoperative systems are 
costly and complex [16].  
Intraoperative fluorescence imaging offers the 
benefits of high contrast and sensitivity, low cost, ease 
of use, safety, and visualization of cells and tissues 
both in vitro and in vivo [17, 18]. Over the past several 
years, a vast amount of published data showed 
improved visualization of cancer tissue over dark 
background by the utilization of different fluorescent 
probes. One example of a clinically evaluated 
fluorescent “Always ON” low molecular weight 
(MW) probe includes a folate receptor-targeted 
fluorophore [19]. The current challenge of near- 
infrared fluorescence (NIRF)-guided surgery is to 
design probes with high selectivity for tumors and 
clear visualization. To that end, different fluorescent 
probes have been developed and studied; these are 
often referred to as “smart” probes. “Smart” probes 
are activated at the tumor site while otherwise they 
remain intact. Thus, in comparison to the “Always 
ON” probes, minimal signal is emitted, and the 
background noise is reduced, leading to an improved 
signal-to-noise ratio and clearer visualization. The 
activation and signal enhancement can occur via 
different triggers or peptide linkers recognized by 
certain enzymes or analytes that are overexpressed in 
the tumor and its surroundings. Recently reported 
Turn-ON probes include fluorescently-tagged 
activatable cell-penetrating peptides (ACPP) [20], low 
MW fluorogenic peptides, and trigger-activated 
analytes [21-25]. The ideal fluorescent probe for 
intra-operative application should possess high tumor 
selectivity and enhanced accumulation while sparing 
the healthy tissue, thus delineating tumor margins in 
real-time during the entire surgical procedure.  
Different low MW molecules used in clinical 
practice suffer from several drawbacks. Indocyanine 
green (ICG), a non-specific, low MW, clinically 
approved near-infrared (NIR) fluorophore, possesses 
a very short plasma half-life of about 2-4 min, 
followed by a slower clearance rate after binding to 
plasma proteins [26]. This, in turns, limits its 
application for prolonged procedures that require 
tumor accumulation and detection during image- 
guided surgery. The FDA-approved 5-aminolevulinic 
acid (5-ALA), a protoporphyrin precursor, generates a 
fluorescence signal upon cellular metabolism. 
However, its broad usage is limited due to insufficient 
accumulation inside tumor cells [27, 28]. Nevertheless, 
many proof-of-principle clinical trials have been 
conducted in several types of surgeries with ICG and 
5-ALA fluorophores [16]. Other reports of activatable 
Turn-ON probes include numerous low MW 
cathepsins-sensitive substrates, most of which show 
fast clearance. As a result, shortly after admini-
stration, their signal is greatly reduced [18]. 
 Polymeric systems hold great potential in 
improving the performance of imaging agents, as they 
do for drugs [29]. A macromolecular carrier can alter 
the biodistribution and pharmacokinetics of the dye. 
While a nanoscale carrier does not extravasate more 
than small molecules from normal vessels, it can 
preferentially extravasate into the tumor site because 
of the tumor leaky vessels, and be retained there due 
to the poor lymphatic drainage. This phenomenon is 
termed the enhanced permeability and retention 
(EPR) effect [30]. We and other groups have shown 
that the signal obtained from the tumor is greater and 
is retained for a longer time for macromolecular 
probes compared with that of low MW fluorescent 
molecules [22, 31, 32]. The general concept of an 
activated Turn-ON polymeric or macromolecular 
probe generating a fluorescence signal was previously 
proposed [33]; however, there have been many 
unique reports on different systems [34, 35], 
mechanisms of activation and/or versatile 
applications [36-38]. Several quantum dots have also 
shown benefits in the fluorescence image-guided 
surgery arena, including bladder cancer resection [35], 
small MW integrin-targeted RGD probes for 
colorectal cancer and ureters [39] and fluorescently- 
tagged targeted antibodies for head-and-neck cancer 
[34]. 
Reinforcement to this strategy of macromolecule 
conjugation with imaging agents is given by 





nanoparticle- or polymer-based imaging probes that 
are under clinical evaluation or recently gained FDA 
approval. Examples include the FDA-approved 
Lymphoseek®, a technetium 99mTc-dextran conjugate 
for sentinel lymph nodes (SLN) identification that has 
shown persistent SLN accumulation for at least 24 h 
[40], a polyethyleneglycol-bound (PEGylated) 
protease activatable fluorescent probe that is in a 
phase 1 clinical trial [41] and an 124I-cRGDY- 
PEGylated core-shell silica nanoparticle [42]. Cysteine 
cathepsins play a pivotal role in the tumor and its 
surroundings, and may assist its progression. It has 
been reported that many tumor types have 
overexpressed activated cathepsins [43, 44]. This 
property can be exploited to rationally design smart 
probes that can be triggered at the tumor site. In this 
study, we report the design, synthesis and 
characterization of three polymeric Turn-ON probes 
that are activated by cathepsin enzymatic degradation 
to generate a fluorescence signal. These Turn-ON 
probes possess unique properties, resulting from 
different structures and activation modes for the 
application of image-guided surgery proposed herein, 
which differentiate them from previously reported 
probes. The first polymeric Turn-ON probe (system 1) 
was recently reported by us [31] and composed of the 
non-degradable N-(2-hydroxypropyl)-methacryl-
amide (HPMA) copolymer backbone bearing 
self-quenched (homo-FRET) NIRF Cy5 dyes. Two 
additional novel polymeric systems (2 and 3) are 
composed of a biodegradable poly-L-glutamic acid 
(PGA) polymeric backbone loaded with 
self-quenched Cy5 molecules (system 2) or 
hetero-FRET-quenched Cy5 and dark quencher 
moieties (system 3) (Figure 1A). The systems utilize 
different mechanisms of activation: In system 1, 
enzymatic cleavage of the Gly-Phe-Leu-Gly (GFLG) 
tetrapeptide linker results in a release of the free dye 
while the polymeric backbone remains intact. In 
systems 2 and 3, the enzymes cleave the polymeric 
backbone of the poly-glutamic acid. Both mechanisms 
eventually release the free dyes, allowing them to 
emit their fluorescence and thus Turn-ON. We set to 
study the different mechanisms and sizes of the 
probes and how they affect their ability to serve as 
imaging agents for image-guided surgery. We 
characterized our conjugates for their hydrodynamic 
diameter, quenching properties, Turn-ON capacity 
and enzymatic efficiency upon incubation with 
cathepsin B (CTSB), one of the members of the 
cysteine cathepsins family. We chose to focus on the 
two leading probes that showed the greatest 
quenching and Turn-ON capacity for further in vivo 
evaluation as image-guided surgery agents. The in 
vitro and in vivo characterization of our Turn-ON 
probes was compared to that of “Always ON” 
(resulted from non-cleavable linker addition or lower 
loading of Cy5 molecules) and Never ON control 
probes. A schematic representation of these different 
control probes is shown in Scheme S1. 
We set out to evaluate and study how the 
differences in size and mechanism of activation 
between our Turn-ON probes may affect their 
potential use as optical guiding tools during surgical 




(HPMA-GFLG-NH2) incorporating 10 mol% of 
GFLG-NH2 was obtained from Polymer Laboratories 
(Church Stretton, UK).  HPMA-GFLG-NH2 has a MW 
of 31,600 Da and a polydispersity (PDI) of 1.66. RPMI 
1640, MEM, fetal bovine serum (FBS), penicillin, 
streptomycin, nystatin, L-glutamine, Hepes buffer, 
non-essential amino acids solution and sodium 
pyruvate were purchased from Biological Industries 
Ltd. (Kibbutz Beit Haemek, Israel). DMEM, Advanced 
DMEM and glutaMAX x100 solutions were purchased 
from Rhenium (Modiin, Israel). Cathepsin B (CTSB) 
enzyme from bovine spleen (CAS no# 9047-22-7) was 
purchased from Sigma-Aldrich (Rehovot, Israel). 
Human recombinant cathepsin S (CTSS) (cat no# 
1183-CY) and cathepsin L (CTSL) (cat no# 952-CY) 
were purchased from R&D Systems, Inc. 
(Minneapolis, US). All other chemical reagents, 
including salts and solvents, were purchased from 
Sigma-Aldrich (Rehovot, Israel). All reactions 
requiring anhydrous conditions were performed 
under an Ar (g) atmosphere. Chemicals and solvents 
were either AR grade or purified by standard 
techniques. 
Synthesis of HPMA copolymer-GFLG-Cy5 
(P-GFLG-Cy5) conjugate 
Cy5-COOH was synthesized as previously 
described [23]. Next, Cy5-COOH fluorophore was 
conjugated with HPMA-GFLG-NH2 copolymer 
precursor in a two-step synthesis. First, Cy5-COOH 
(45 mg, 0.069 mmol) was dissolved in 0.7 mL 
anhydrous N,N-dimethylformamide (DMF). 
N-hydroxysuccinimide (NHS) (11.9 mg, 0.103 mmol) 
and N,N'-dicyclohexylcarbodiimide (DCC) (21.332 
mg, 0.103 mmol) were added in order to activate the 
free carboxylic group of the fluorophore for further 
coupling to the HPMA-GFLG-NH2 copolymer 
precursor. The reaction mixture was stirred at room 
temperature (RT) in the dark for 12 h. Then, 
HPMA-GFLG-NH2 copolymer precursor (100 mg, 





0.573 mmol) was dissolved in 0.5 mL anhydrous DMF 
and added to the reaction mixture. The reaction 
progress was followed by high pressure liquid 
chromatography (HPLC) (UltiMate® 3000 Nano LC 
systems, Dionex). At the end of the reaction, the 
solvent was removed partially by high vacuum and 
precipitated in cold ether. The precipitate was further 
washed with acetone and dried under vacuum. 
Purification of the conjugate by size exclusion 
chromatography (SEC) was performed using an 
ÄKTA FPLC system (Amersham Biosciences) with 
Sephadex LH-20 columns in MeOH using a flow rate 
of 1.0 mL/min and UV/Vis detection. In order to 
remove all excess of free fluorophore, the residue was 
dissolved in water and dialyzed for 1 day at 4 °C (MW 
cut-off (MWCO) 6-8 kDa) against DI water. The 
conjugate was isolated by freeze-drying. Cy5 loading 
was determined using SpectraMax M5e multi- 
detection reader. The absorbance of conjugated Cy5 
was measured and compared to that of free Cy5. 
Quenching efficiency was expressed as a percentage 
of the fluorescence intensity of the HPMA 
copolymer-GFLG-Cy5 (P-GFLG-Cy5) conjugate (λEm= 
670 nm) compared with the emission of the free Cy5 at 
an equivalent concentration. MW theoretical value of 
the conjugate was determined according to 
HPMA-GFLG-NH2 copolymer precursor MW, and 
Cy5 molecules loading (13.2 weight percent (wt%), 
4.06 mol%). 1H NMR and HPLC characterizations are 
presented in Figure S1 and Figure S3. 
Synthesis of PGA-Cy5 (PC) conjugate 
Poly-L-α-glutamic acid (PGA) was synthesized 
as previously described [45] by ring opening 
polymerization that started from α-N-carboxy-
anhydrides (NCA) of a γ-benzyl-L-glutamate 
preparation. Neopentyl-NH3BF4 was used as an 
initiator. The PGA polymer obtained had a MW of 
9959 and PDI of 1.166, as characterized by multi-angle 
static light scattering (MALS) described later in this 
section. Cy5-NHBoc and dark quencher, Q-NHBoc, 
were conjugated directly to a PGA backbone in two 
similar coupling reactions. In order to activate the 
fluorophore, tert-butyloxycarbonyl protecting group 
(Boc) was removed from the reactive amine by mixing 
Cy5-NHBoc (15.5 mg, 0.0194 mmol) with 
trifluoroacetic acid (TFA) and dichloromethane 
(DCM) mixture (1:1) for 5 min following immediate 
high-vacuum evaporation. Next, PGA (25 mg, 0.194 
mmol) was dissolved in 2 mL anhydrous 
N,N-dimethylformamide (DMF) and then transferred 
into the flask containing Cy5-NH2. Bis (2-oxo-3- 
oxazolidinyl) phosphinic chloride (BOP-Cl) (9.867 mg, 
0.0388 mmol) was dissolved in 500 µL anhydrous 
DMF, and 4-dimethylaminopyridine (DMAP) (5.681 
mg, 0.0465 mmol) dissolved in 500 µL anhydrous 
DMF were added to the reaction mixture in order to 
activate the carboxylic acid residues on the PGA. 
Finally N,N-diisopropylethylamine (DIPEA) (5 µL, 
0.0155 mmol) was added. The reaction was mixed for 
4 h in an ice bath, and then the ice was removed and 
the reaction continued at RT for an additional 48 h 
under argon (Ar(g)) atmosphere. The reaction progress 
was followed by thin layer chromatography (TLC). At 
the end, 3 mL of 10% sodium chloride solution (NaCl) 
was added and the mixture was acidified to pH 2.5 by 
addition of 0.5 M hydrochloric acid (HCl) solution. 
The reaction was stirred for 1 h at RT and then the 
solvent was removed by high vacuum. The obtained 
solid was washed three times with acetone- 
chloroform (4:1) mixture, salted in 0.25 M sodium 
bicarbonate solution (NaHCO3) and dialyzed against 
DI water for 48 h at 4 °C (MWCO 3.5 kDa). Final 
purification of the conjugate by SEC was performed 
using an ÄKTA FPLC system (Amersham 
Biosciences) using HiTrap desalting columns 
(Sephadex G-25 Superfine) in DDW with a flow rate of 
1.0 mL/min; UV/Vis detection was monitored at 220, 
600 and 650 nm. The conjugate was dried by 
freeze-drying and characterized by HPLC (UltiMate® 
3000 Nano LC systems, Dionex). Cy5 loading and 
quenching efficiency were determined as described 
above. MW theoretical value of the conjugate was 
determined according to PGA polymeric precursor 
MW, and Cy5 loading (5.7 wt%, 1.13 mol%). 1H NMR 
characterizations are presented in Figure S2. 
Synthesis of PGA-Cy5-Quencher (PCQ) 
conjugate 
Next, the obtained PC conjugate was coupled 
with an aminated dark quencher (Q-NHBoc) [23], in a 
similar procedure as described above. Briefly, 
Q-NHBoc (15 mg, 0.0075 mmol) was deprotected, 
dried under vacuum and then the Q-NH2 was 
re-dissolved in anhydrous DMF. PC (15 mg, 0.075 
mmol) was added to the reaction and stirred. BOP-Cl 
(3.818 mg, 0.015 mmol) and DMAP (2.749 mg, 0.0225 
mmol) dissolved as above in anhydrous DMF and 
were added to the reaction mixture and finally, 
DIPEA (5 µL, 0.0155 mmol) was added. The reaction 
was mixed for 4 h in an ice bath, and then for an 
additional 48 h at RT under Ar(g) atmosphere. The 
reaction progress was followed by HPLC. At the end, 
as described above, NaCl was added, the mixture was 
acidified and stirred for 1 h at RT followed by solvent 
removal under high vacuum. The obtained solid was 
washed with acetone-chloroform mixture, salted in 
NaHCO3 solution and dialyzed against DI water for 
48 h at 4 °C (MWCO 3.5 kDa), as described above. 
Final purification of the conjugate by SEC was 





performed as described above followed by 
freeze-drying of the conjugate and HPLC 
characterization. The loading of the conjugated 
quencher molecules was determined using 
SpectraMax M5e multi-detection reader. The 
absorbance of conjugated quencher was measured 
and compared to that of free quencher. Quenching 
efficiency of the final conjugate was expressed as a 
percentage of the fluorescence intensity of the 
PGA-Cy5-Quencher (PCQ) (λEm = 670 nm) compared 
with the emission of free Cy5 at an equivalent 
concentration. The theoretical MW of the conjugate 
was determined according to PGA polymeric 
precursor MW, Cy5 and quencher loading ((5.7 wt%, 
1.13 mol%) and (4.1 wt%, 0.83 mol%), respectively). 
HPLC characterization is presented in Figure S3. 
Multi-angle static light scattering (MALS) 
MW and PDI analysis of the PGA polymer were 
performed on an Agilent 1200 series HPLC system 
(Agilent Technologies Santa Clara, CA, US) equipped 
with a multi-angle light scattering detector (Wyatt 
Technology Corporation Santa Barbara, US), using 
Shodex Kw404-4F column (Showa Denko America, 
Inc.) in phosphate-buffered saline (PBS) with a flow 
rate of 0.3 mL/min. 
Transmission electron microscopy (TEM) 
P-GFLG-Cy5 (1 mg/mL in saline) was adsorbed 
on formvar/carbon-coated grids and stained with 2% 
aqueous uranyl acetate (negative staining). TEM 
images were taken using a JEM 1200EX TEM (JEOL 
Ltd., Tokyo, Japan). Diameters were measured by 
measureIT software; the particle distribution is the 
average of 3 fields of view, 10 particles per field. 
Scanning electron microscopy (SEM) 
PC (0.01 mg/mL in DDW) and PCQ (0.1 mg/mL 
in DDW) samples were dropped on a silicon wafer 
and blotted with cellulose paper. SEM images were 
taken using a Quanta 200 FEG Environmental SEM 
(FEI, Oregon, USA) at high vacuum and 5.0 kV. 
Diameters were measured by measureIT software; the 
particle distribution is the average of 3 fields of view, 
20 particles per field. 
Dynamic light scattering (DLS) analysis  
 The mean hydrodynamic diameter of the PC 
conjugate was measured using a DynaPro Plate 
Reader II instrument at an 830 nm laser wavelength 
(Wyatt Technology Corporation, Santa Barbara, CA 
93117 USA). The mean hydrodynamic diameter of the 
P-GFLG-Cy5 and PCQ conjugates was measured 
using a Möbius instrument at a 540 nm laser 
wavelength using a 532 nm longpass filter (Wyatt 
Technology Corporation, Santa Barbara, CA 93117 
USA). P-GFLG-Cy5, PC and PCQ samples were 
prepared by dissolving 0.5, 1 and 1 mg/mL of 
polymer conjugates in saline, DDW and DDW, 
respectively. All measurements were performed at 25 
°C.  
Cathepsin B (CTSB) activity assay 
Cy5 enzymatically directed release from the 
conjugates was studied in vitro. P-GFLG-Cy5, PC and 
PCQ conjugates (5 µM Cy5-eq. concentration) were 
incubated at 37 °C with CTSB (0.56 U/mL) in freshly 
prepared activity phosphate buffer (0.1 M, pH 5.5) 
containing 0.05 M NaCl, 1 mM ethylenediamine-
tetraacetic acid (EDTA) and 5 mM reduced 
glutathione (GSH). For the controls, conjugates were 
incubated in the absence of CTSB or in the presence of 
CTSB inhibitor, CA-074 Me (100 µM), in the same 
conditions. The inhibitor concentration of 100 µM was 
chosen to inhibit 0.56 U/mL of CTSB. This ratio of 
about 200-fold was determined according to the 
inhibition concentration dependence evaluation. In 
this evaluation, inhibitor concentrations above 41.67 
µM inhibited 0.2 U/mL of CTSB (about 200-fold of 
enzyme concentration over inhibitor concentration) 
(Figure S4E-F). Free Cy5 release was monitored by 
measuring the change in the fluorescence intensity at 
sequential time points. The fluorescence 
measurements were carried out using SpectraMax 
M5e multi-detection reader (λEx: 630 nm, λEm: 670 nm, 
filter: 665 nm). Samples (100 µL) were collected every 
24 h (up to 70 h) and immediately analyzed.  
In vitro enzyme kinetics of Turn-ON probes 
CTSB enzyme (0.2 U/mL, pH 5.5) was 
challenged with increasing concentrations (triplicates 
of 0 to 60 µM Cy5-eq. concentration) of P-GFLG-Cy5 
and PCQ substrates. Turnover curves were followed 
by measuring the increase in Cy5 fluorescence (λEx: 
630 nm, λEm: 670 nm, filter: 665 nm) using SpectraMax 
M5e multi-detection reader. The conversion from 
fluorescence to concentration of product formed was 
calculated according to a free Cy5 calibration curve. 
The initial velocity of the probe cleavage by CTSB was 
calculated from the linear portion of the curve of each 
Turn-ON probe concentration. The kinetic parameters 
(KM, Kcat and KM/Kcat) were obtained by fitting the 
experimental data to the Michaelis Menten equation, 
Vt = Vmax * [S] / (KM + [S]), using GraFit 7.0 software.  
Cell culture 
Human breast adenocarcinoma MDA-MB-231 
and MCF7, murine mammary 4T1, murine melanoma 
B16-F10 and human melanoma A375, WM115 and 
WM239A cell lines were purchased from the 
American Type Culture Collection (ATCC Manassas, 
VA, USA). 131/4-5B1 human melanoma 





brain-metastasizing cell line was a kind gift from Prof. 
Robert Kerbel (University of Toronto, Canada) [46] 
and Ret-mCherry melanoma sorted (RMS) cells, 
derived from MT/Ret transgenic mice were provided 
by Dr. Viktor Umansky (DKFZ, Germany) and were 
transduced by us with mCherry as described 
previously [47]. Murine melanoma D4M.3A cell line 
was kindly provided by Prof. David W. Mullins 
(Dartmouth College, Hanover). PD-MBM1, 
PD-MBM2 and PD-MBM3 cell lines isolated from 
patient-derived melanoma brain metastases were 
obtained from Tel Aviv Sourasky Medical Center 
under an approved IRB protocol. All cell lines were 
cultured in growing media supplemented with 10% 
fetal bovine serum (FBS), 100 μg/mL streptomycin, 
100 IU/mL penicillin, 12.5 IU/mL nystatin and 2 mM 
L-glutamine (unless otherwise stated). The cell lines 
were cultured in the indicated media and had the 
following growing additives where specified; MCF7, 
MDA-MB-231, B16-F10, PD-MBM1, PD-MBM2 and 
PD-MBM3 cells were cultured in Eagle's Medium 
(DMEM). 4T1 cells were cultured in RPMI 1640 
supplemented with 10 mM Hepes buffer, 1 mM 
sodium pyruvate and 2.5 g/L D-glucose. 131/4-5B1, 
WM239A and RMS cells were cultured in RPMI 1640. 
A375 cells were cultured in RPMI as described above 
with addition of 1 mM sodium pyruvate and 10 mM 
HEPES buffer. WM115 cells were cultured in MEM 
supplemented with 1 mM sodium pyruvate and 1% 
non-essential amino acids (NEAA). D4M.3A cells 
were cultured in DMEM advanced medium 
supplemented with 5% FBS and 1% L-GluMAX. 
Phenol red-free media were used for the fluorescence 
sensitive assays. Cells were grown at 37 °C and 5% 
CO2.  
Labeling OCT tissue sections with NIRF-ABP 
Normal mammary fat pad tissues, normal 
human skin, 4T1 mammary tumors and 131/4-5B1 
melanoma tumors were embedded in optical cutting 
temperature (OCT) and snap-frozen in liquid nitrogen 
prior to cryosectioning. Normal human skin was 
collected after obtaining written informed consent 
from research subjects at Hadassah Medical Center, 
Jerusalem, under an approved institutional review 
board (IRB) (HMO-14-0367). Normal mammary 
sections of 15 µm and 10 µm sections for the rest of the 
tissues were mounted on histology glass slides and 
fixed with paraformaldehyde 4% in PBS for 30 min at 
4 °C, then washed 3 times with PBS for 5 min. For 
cathepsins staining, slides were incubated for 1 h with 
0.25 μΜ GB123 at 37 °C in a reaction buffer (50 mM 
acetate, 4 mM DTT and 5 mM MgCl2, pH 5.5) with or 
without pre-incubation with 2.5 μM GB111-NH2, a 
cathepsin inhibitor [49]. Slides were then washed 
overnight in phosphate-buffered saline at 4 °C. Slides 
that were previously treated with GB111-NH2 were 
treated with additional 1 µM GB111-NH2 and 
incubated for 1 h at 37 °C. Finally, all slides with 
labeled tissues were mounted with ProLong® Gold 
antifade reagent with 4′ 6-diamidino-2-phenylindole 
(DAPI). The stained sections were visualized using 
confocal microscopy with DAPI and Cy5 lasers and 
filters as described below. 
Labeling of lysed tissues with NIRF-ABP 
Normal mammary fat pad and normal human 
skin tissues, MDA-MB-231 and 4T1 mammary 
tumors, 131/4-5B1, D4M.3A, A375 and RMS 
mCherry-labeled melanoma tumors were snap-frozen 
in liquid nitrogen and lysed on ice with RIPA buffer 
by means of gentleMAX dissociator. The obtained 
lysates were centrifuged for 10 min (18500 rcf, 4 °C), 
supernatant was collected and protein amount was 
quantified by Bradford assay. An equal amount of 30 
µg protein was pretreated with 5 µM GB111-NH2, or 
DMSO (indicated samples) for 45 min in reaction 
buffer as described in the supplementary information, 
at 37°C. GB123 (2 µM) was added to all samples for 90 
min at 37 °C. The reaction was terminated by addition 
of 5X sample buffer (10% glycerol, 50 mM Tris HCl, 
pH 6.8, 3% SDS and 5% β-mercaptoethanol) and 
boiling. Finally, proteins were separated by 12.5% 
SDS-PAGE and scanned for fluorescently labeled 
proteases by a Typhoon scanner FLA 9500 at 
excitation/emission wavelengths 635/670 nm.  
Confocal microscopy 
Intact cells and explants of normal or tumor 
tissue sections labeled with GB123 as well as 
fluorescent explant tumor tissues following i.v. 
injection of P-GFLG-Cy5 and PCQ were monitored 
utilizing Zeiss Meta LSM 510 and Leica TCS SP8 
confocal imaging systems with 60× oil objectives 
(Leica Microsystems, Wetzlar Germany). All images 
were taken using a multi-track channel acquisition to 
prevent emission crosstalk between fluorescent dyes.  
In vitro co-localization with lysosomes and 
cellular uptake of Turn-ON probes 
For the in vitro co-localization of Turn-ON 
probes with lysosomes, 131/4-5B1 and 4T1 cells 
(2,000,000 cells/well or 1,000,000 cell/well 
respectively) were seeded in 10 cm petri dishes one or 
two days before treatment, respectively. For 
co-localization with lysosomes, cells were treated 
with 500 nM Cy5-eq. concentration P-GFLG-Cy5 and 
PC for 2 h. In the last 0.5 h, 100 nM LysoTracker™ 
Green DND-26 (Life technologies) was added to the 
10 cm petri dishes. For cellular uptake evaluation, 
cells were treated with 500 nM Cy5-eq. concentration 





of PCQ or P-GFLG-Cy5 conjugates and with free Cy5 
in the same concentration for 30 and 60 min, 
respectively. Growth medium was replaced with the 
treatment solutions. Cells were washed with PBS and 
incubated with phenol red-free RPMI medium for 1 h. 
For the Turn-ON evaluation in living cells, cells were 
washed with PBS and incubated with phenol red-free 
RPMI medium for 0, 0.5, 1 and 16 h post treatment 
removal. Cells were washed 3 times with PBS and 
detached from the petri dish by incubation with 
phenol red-free trypsin for 5 min. Then, 6 mL of 2% 
FBS/PBS was added and the cells were centrifuged 
for 7 min at 200 rcf (4 °C). The cells were resuspended 
in 50 µL of 2% FBS/PBS and analyzed using an 
ImageStream®X Mark II Imaging Flow Cytometer for 
co-localization or cellular uptake by fluorescence 
signal evaluation. Similarity (co-localization) 
threshold was set as above 1.5 (AU) fluorescence 
signal intensity of red and green overlapping pixels. 
Animals and tumor cell inoculation 
BALB/c mice (aged 6–8 weeks) were inoculated 
with 1×106 4T1 cells into the mammary fat pad using a 
27-gauge needle, and SCID mice were inoculated 
intra-dermally with 5×105 131/4-5B1 or A375 
mCherry-labeled cells. Nu/nu mice were inoculated 
intra-mammary with 1×106 MDA-MB-231 cells. 
C57BL/6J mice were inoculated intra-dermally with 
5×105 D4M.3A and RMS cells. Intra-dermal and 
intra-mammary injection volumes were 50 and 100 
µL, respectively. Mice were monitored every other 
day for body weight changes and tumor growth was 
measured using a caliper. Tumor volume was 
calculated using the standard formula: length × 
width2 × 0.52. Mice bearing 4T1 tumors that did not 
undergo surgery were euthanized 22 days post 
inoculation according to IACUC regulations (tumor 
sizes were above 1000 mm3).  
Fluorescence imaging 
BALB/c mice bearing 4T1 tumors (~100 mm3) 
were injected intravenously (i.v.) with P-GFLG-Cy5 
(10 μM Cy5-eq. concentration, 200 µL saline; 4-9 mice 
per group). SCID mice bearing 131/4-5B1 melanoma 
tumors (~100-150 mm3) were injected i.v. (10 μM 
Cy5-eq. concentration, 200 µL) with PCQ. 
Fluorescence signal within tumor was assessed using 
the non-invasive imaging system CRI MaestroTM at 
different time points, starting at 1 min, up to 24 h 
following injection into BALB/c mice or into SCID 
mice. Multispectral image cubes were acquired 
through the 650–800 nm spectral range in 10 nm steps 
using excitation (635 nm longpass) and emission (675 
nm longpass) filter sets. Mouse auto-fluorescence and 
undesired background signals were eliminated by 
spectral analysis using the linear unmixing algorithm.  
Survival surgery 
Survival surgeries with P-GFLG-Cy5 fluores-
cence guidance (IGS group) or under white light 
(control group) were performed on xenografts of 4T1 
or 131/4-5B1 cells. Both groups had similarly sized 
4T1 or 131/4-5B1 tumors (~100-150 mm3). Animals 
were anesthetized with 100 mg/kg ketamine and 10 
mg/kg xylasin and hair was removed with a 
depilatory cream. All surgical procedures were 
performed in sterile conditions. The IGS group was 
injected i.v. with P-GFLG-Cy5 or PCQ probes (10 µM 
Cy5-eq. concentration, 200 µL saline). Four hours 
following i.v. injection, intravital imaging by CRI 
MaestroTM was performed, as described above, before 
surgery and during all steps of surgery (intact animal, 
following skin incision over the tumor and during 
tumor excision). The control groups underwent 
surgery under white light illumination, or under 
5-ALA or ProSense® 680 guidance. 5-ALA (0.1 mg/g) 
was administered per os 4 h prior to surgery. 
Prosense® 680 (2 nmol in 150 µL PBS pH 7.4) was 
administered i.v. into the tail vein 4 or 24 h prior to 
surgery. Hemostasis was measured with a handheld 
hemostat. Images of the fluorescence signal were 
displayed on an adjacent monitor and all Cy5-positive 
tissue foci (suspected as tumor tissues) were excised. 
Following completion of tumor excision, both with or 
without fluorescence guidance, skin incisions were 
sewn and animals were returned to their cages to 
recover from the anesthesia. Complete tumor excision 
was assessed by fluorescence signal (background 
level, n=4) or white light (control group, n=4). 
Post-surgery tumor recurrence follow-up 
Both IGS and control groups (no guidance, 
5-ALA and ProSense® 680) were monitored for tumor 
recurrence. All mice were weighed twice a week. 
Tumor follow-up was monitored both by palpitation 
of the surgical area and by fluorescence imaging 4 h 
following i.v. injection of P-GFLG-Cy5 (10 µM Cy5-eq. 
concentration, 200 µL saline). Recurrence was 
observed by optical (fluorescence) imaging and by 
histology with H&E staining. Three exclusion criteria 
were determined in advance: above 10% weight-loss, 
tumor recurrence size was above 400 mm3 and/or 
neurological disorders. Mice with one of the above 
criteria were assessed by CRI MaestroTM imaging and 
by white light for metastasis spread and then 
euthanized.  
Tissue histology 
As described above, during post-surgery tumor 
recurrence follow-up, mice were imaged by CRI 
MaestroTM (filter set: λEx: 635 nm, λEm: 650-800 nm, 





filter: 675 nm) 4 h post i.v. injection of P-GFLG-Cy5 
(10 µM Cy5-eq. concentration, 200 µL). Tissues that 
showed an increased Cy5 signal were suspected as 
recurrent or metastatic cancerous tissues, and were 
then excised and stained for H&E for further 
histo-pathological analysis. The suspected cancerous 
tissues were embedded in paraffin or OCT. Prior to 
OCT embedding, excised tissues were incubated with 
4% PFA in PBS for 4 h followed by incubation in PBS 
for 12 h and 1 M sucrose (BioLab) overnight. For 
paraffin-embedded fixation, tissues were kept for 48 h 
in 4% PFA in PBS, then processed using a Tissue 
Processor (Leica) for 10 h and then embedded in 
paraffin using a Leica Tissue Embedder. 5 µm sections 
were deparaffinized, rehydrated, and stained by 
hematoxylin and eosin (H&E). Excised sternum 
tissues were fixed in 4% PFA and decalcified for 14 
days in 14% ethylenediaminetetraacetic acid (EDTA), 
embedded in OCT and snap-frozen in liquid nitrogen 
prior to cryosectioning. 10 μm sections were obtained 
and stained by H&E. Sequential sections obtained 
from IGS were mounted with ProLong® Gold 
antifade reagent with DAPI and examined by confocal 
microscopy to evaluate Cy5 internalization into cells. 
Statistical methods 
Data is expressed as mean ± standard deviation 
(SD) for in vitro assays or ± standard error of the mean 
(SEM) for in vivo results. Statistical significance was 
determined using one-way ANOVA. All experiments 
were performed in triplicate and repeated at least 
three times. 
Ethics statement 
All animal procedures were approved and 
performed in compliance with the standards of Tel 
Aviv University, Sackler School of Medicine Institu-
tional Animal Care and Use Committee (IACUC).  
Results  
Design of self-quenched/FRET-based Turn-ON 
probes activated by cathepsins 
Cysteine cathepsins are lysosomal cysteine 
proteases overexpressed in several tumor types [50]. 
The high levels of cathepsins can be harnessed for 
specific activation at the tumor site. We exploited this 
property in order to design several Turn-ON probes, 
which can be activated to generate a fluorescence 
signal upon reaction with tumor cathepsins. The 
Turn-ON probes are otherwise optically silent due to 
Förster resonance energy transfer (FRET) between 
dye-dye (Cy5-Cy5) or dye-dark quencher (Cy5- 
quencher) molecules. We designed three 
cathepsins-activatable polymeric Turn-ON probes 
composed of two different polymeric backbones as 
the macromolecular carrier. The first, system 1, was 
recently reported by our group [31], and is composed 
of HPMA copolymer bearing covalently bonded Cy5 
molecules via a tetra peptide spacer, Gly-Phe-Leu-Gly 
(GFLG), which is a known cathepsins substrate. The 
activation to its Turn-ON state at the tumor site occurs 
by cathepsin cleavage of the tetra peptide. Upon 
cleavage of the GFLG linker, Cy5 molecules that are 
covalently bound to it are detached and move apart, 
resulting in elevation of the fluorescence signal 
(Figure 1A). The second polymeric backbone, utilized 
in systems 2 and 3, is poly-L-glutamic acid (PGA), 
which is biodegradable by cathepsins. PGA was 
designed to be covalently linked to multiple Cy5 
molecules to generate the PC conjugate, which 
possess self-quenching interactions between the 
fluorophores (system 2). PCQ was designed to be 
generated from the former PC by the addition of 
quencher molecules, thus introducing FRET 
quenching interactions into this system (system 3). 
The three polymeric systems are designed to be 
activated to their Turn-ON state by two different 
mechanisms. The first activation is by the GFLG linker 
cleavage and the second is by backbone degradation 
(Figure 1A). We sought to compare the two systems’ 
fluorescence signal recovery upon challenging with 
CTSB in vitro and cathepsins in vivo to determine their 
potential application as guiding agents for real-time 
image-guided surgery. Our Turn-ON probes’ 
characterizations were compared to those of “Always 
ON”, non-cleavable and “Never ON” probes and are 
described in Scheme S1. 
 
Synthesis and characterization of HPMA 
copolymer-GFLG-Cy5 (P-GFLG-Cy5) 
Turn-ON probe 
 P-GFLG-Cy5 conjugate was synthesized bearing 
4.06 mol% loading of Cy5 (6.3 dyes per polymer 
chain). Its fluorescence spectrum was characterized in 
order to evaluate both the self-quenching of the 
conjugated fluorophore and its biodegradability by 
cathepsins. The synthesis scheme of the P-GFLG-Cy5 
conjugate is represented in Figure 1B. The 
hydrodynamic diameter size distribution of 
P-GFLG-Cy5 conjugate was determined using a 
Möbius dynamic light scattering (DLS) analyzer. The 
mean hydrodynamic diameter was ~7 nm (Figure 2A, 
Table 1), which correlates well with imaging results 
obtained from transmission electron microscopy 
(TEM) analysis, showing an average particle size of 
8.5 ± 3.5 nm (Figure 2B, Table 1). This particle size is 
ideal for in vivo imaging as recent clinical trials were 
conducted using ~7 nm particles [51]. In addition, this 
size is below 10 nm, which is reported to be optimal 
for imaging and diagnostics for surgical procedures, 





due to their better escape ability from the 
mononuclear phagocyte system, compared to 
particles with bigger hydrodynamic diameter [52]. 
Furthermore, this particle is small enough to quickly 
travel with the lymphatic flow to the tumor, but large 
enough to retain there via the EPR effect, in order to 
be detected and optically guide surgical procedures. 
Table 1 summarizes the properties determined for 
each conjugate.  
 

















P-GFLG-Cy5 36.41 7.17±1.17 8.5±3.5 4.06 N/A 
PC 10.56 7.9±0.45 
247.5±11.2 
220±45 1.13 N/A 
PCQ 11.04 152±41 115±25 1.13 0.83 
atheoretical value, bdetermined by DLS instrument cdetermined by spectroscopic 




Figure 1. Design and synthesis of self-quenched HPMA copolymer-GFLG-Cy5 (P-GFLG-Cy5), PGA-Cy5 (PC) and FRET-based PGA-Cy5-Quencher 
(PCQ) Turn-ON probes. (A) Schematic representation of two different pathways of the probes’ degradation by cysteine cathepsins, leading to their activation and increase 
in the fluorescence signal, as the fluorophore molecules are distanced from each other and quenching is terminated. (B) Synthesis scheme of P-GFLG-Cy5 (System 1), PC (System 
2) and PCQ (System 3) Turn-ON probes. 






Figure 2. Physicochemical characterization of the Turn-ON probes. (A) DLS measurements of the hydrodynamic diameter of P-GFLG-Cy5 (0.5 mg/mL, saline), PC (1 
mg/mL, DDW) and PCQ (1 mg/mL, DDW) conjugates. (B) Electron microscopy of (from left to right) a representative TEM image of P-GFLG-Cy5 (1 mg/mL, saline), and 
representative SEM images of PC (0.01 mg/mL, DDW) and PCQ (0.1 mg/mL, DDW) conjugates. TEM and SEM images are representative of 3 fields of view, with 10 or 20 particles 
per field, respectively. (C) i. Effect of Cy5 loading on the quenching efficiency of P-GFLG-Cy5 conjugates with different payloads of Cy5. ii. Effect of the addition of quencher 
molecules to generate FRET PCQ system on the quenching efficacy vs. a self-quenching PC system. All conjugates were measured at the same Cy5-eq. concentration (5 μM). 
Fluorescence intensity decreased with increasing payload of Cy5 on HPMA copolymer conjugates and when introducing quencher molecules to generate PCQ conjugate. Filter 
set: λEx: 630 nm, filter: 665 nm, λEm: 670 nm. The data are presented as mean ± SD (n = 3). 
 
Synthesis and characterization of PC and PCQ 
Turn-ON probes  
Two PGA-based conjugates were synthesized, 
PC (1.13 mol% loading of Cy5) and PCQ (1.13 mol% of 
Cy5 and 0.83 mol% loading of quencher). The 
synthesis scheme is depicted in Figure 1B. Their 
hydrodynamic size distributions were analyzed by 
DLS. The PC conjugate size distribution was found to 
have two main populations of 7.9 ± 0.45 and 247 ± 11.2 
nm (Figure 2A, Table 1). The smaller population was 
measured to be 25% of the mass population according 
to DLS measurement. The larger population 
displaying a size of around 247 nm is probably due to 
supramolecular assemblies of the conjugate at the 
measured concentration. The PCQ conjugate size was 
determined by DLS to be 152 ± 41 nm (Figure 2A, 
Table 1). These results were in good correlation with 





the imaging results obtained from the SEM analysis 
(Figure 2B, Table 1). The particle measurements for 
PC and PCQ conjugates were 220 ± 45 nm and 115 ± 
25 nm, respectively. SEM measurement of PC 
conjugate showed the larger population due to the 
limit of detection sensitivity of this method. The 
slightly larger size measured by DLS relative to that 
by SEM may be attributed to the larger hydrodynamic 
size of particles in solution, which includes the 
attached water molecules solvating the polymer [53].  
Turn-ON probes quenching capacity increased 
with higher dye or quencher payloads 
As previously reported, we postulated that the 
loading of the fluorophore is critical for optimal 
performance [54]. At low fluorophore loading, only 
limited quenching may be observed; these probes 
may also be referred to as Always ON probes. 
However, at high fluorophore loading, Turn-ON may 
not occur due to steric hindrance between the enzyme 
and its target site [54]. These probes may also be 
referred to as Never ON probes. To define the optimal 
loading of Cy5 dyes on HPMA copolymer for efficient 
quenching, two P-GFLG-Cy5 conjugates bearing 
different Cy5 loadings were synthesized and their 
fluorescence spectra were characterized (Figure 2Ci). 
As expected, higher loading of Cy5 molecules on the 
probe led to increased quenching efficiency, as 
reflected by a lower fluorescence signal, resulting 
from the close proximity of one dye to another. In 
contrast, at low fluorophore loading, only limited 
quenching was observed (Figure 2C). Figure 2Ci 
demonstrates that for 0.81% Cy5 loading (1.4 dyes per 
polymer chain) and 4.06% (6.3 dyes per polymer 
chain), the signal intensity was reduced to 75% and 
27%, respectively, relative to free Cy5. Furthermore, 
we compared the addition of dark quencher 
molecules generating FRET, to self-quenched 
(homo-FRET) Cy5 molecules on the PGA polymeric 
backbone. Indeed, for PCQ, the FRET-based 
conjugate, there was a higher quenching efficiency in 
comparison with the PC, a self-quenched Cy5-bearing 
PGA polymer. The fluorescence signal was decreased 
from 84% to 20% of an equi-molar free Cy5 
concentration (Figure 2Cii). The fluorescence signal of 
free Cy5 was set as 100%. As control, Always ON and 
Never ON probes were synthesized at low (Always 
ON) and high (Never ON) loading of PGA bearing 
Cy5 probes (0.56 mol% and 12.5 mol%, respectively). 
A middle payload of 3.3 mol% Cy5 was compared as 
well, as an additional self-quenched Turn-ON probe. 
As expected, the lowest Cy5 loading (0.56 mol%) was 
not quenched at all, and was referred as our Always 
ON probe, while the medium Cy5 loading (3.3 mol%) 
resulted in decreased quenching compared to the 
highest quenching of the conjugate bearing the 
highest Cy5 loading (12.5 mol%), and was referred as 
our Never ON probe (Figure S4A, C). 
In vitro and in vivo cathepsin enzymes activity 
We first validated the activity of cathepsins in 
multiple cancer cell lines. The activity was evaluated 
by a fluorescently labeled cathepsins activity-based 
probe (ABP), GB123, and validated by a cathepsins 
inhibitor, GB111-NH2 [48, 49]. We isolated the 
proteins from mammary adenocarcinoma cell lines 
(murine 4T1 and DA3, human MDA-MB-231 and 
MCF7) and from melanoma cell lines (murine B16-F10 
and RMS, human A375, WM115 and patient-derived 
PD-MBM1, PD-MBM2, PD-MBM3). Cathepsins were 
found to be highly active in most of the tested 
melanoma cell lines (Figure S5A). MDA-MB-231 cell 
line did not show high cathepsin activity in vitro; 
however, it is established that cathepsins are 
overexpressed in those tumors in vivo as a result of 
immune cell recruitment to the tumor 
microenvironment [55]. In order to demonstrate a 
Turn-ON activation in vivo, we further evaluated the 
activity of cathepsins in tumor tissues lysates of 
melanoma and mammary adenocarcinoma tumors. 
Orthotopic tumor tissues of melanoma RMS, D4M.3A, 
A375 and 131/4-5B1 and mammary adenocarcinomas 
4T1, 4T1 tumor recurrence and MDA-MB-231 were 
lysed and proteins were extracted. We found high 
cathepsins activity in the tumors in comparison with 
normal tissues (skin or mammary fat pad), both by 
evaluation of mammary and melanoma cancer cell 
lines (Figure S5A), tumor tissue, skin and mammary 
fat pad lysates (Figure 3A-B) and by scanning tumor 
and healthy sections using confocal microscopy 
(Figure 3C-D). The tissue lysate of the recurring 4T1 
tumor showed a similar activity of cathepsins in 
comparison with the original 4T1 tumor. Treatment 
with GB111-NH2, a cathepsins inhibitor served as 
control, marked as (+), and was added to the samples 
before and during treatment with the labeled ABP, 
GB123. As expected, the tumor lysates pretreated with 
the inhibitor as control (+), did not exhibit the active 
cathepsins band, since it inhibits the enzyme activity 
without labeling it.  
In vitro Turn-ON capacity and enzymatic 
degradation kinetics of the activatable probes 
CTSB is one of the members of the cysteine 
cathepsins family. CTSB-mediated degradation and 
release of Cy5 from P-GFLG-Cy5 and PCQ over time 
is described in Figure 4A-B. In order to evaluate the 
increase in fluorescence intensity due to CTSB 
enzymatic cleavage, the Turn-ON probes were 
incubated in the presence of CTSB (37 °C, pH 5.5) and 





the release of Cy5 was assessed by fluorescence signal 
measurements (Figure 4A). Samples (100 µL) were 
collected at different time points and measured by a 
spectrophotometer. As expected, measured 
fluorescence intensity dramatically increased over 
time and plateaued after 44 h for P-GFLG-Cy5. In the 
absence of the enzyme or upon incubation of the 
enzyme with CTSB inhibitor (CA-074 Me), the 
increase in fluorescence signal was negligible. 
Monitoring the release of Cy5 by HPLC is presented 
in Figure S6. The Cy5 release kinetics of the two 
different Turn-ON probes were quite similar despite 
the different sites of degradation, i.e., GFLG linker vs. 
PGA polymeric backbone of the P-GFLG-Cy5 and 
PCQ, respectively. Next, we evaluated CTSB activity 
on our control probes. These probes included Always 
ON (PC 0.56 mol%), Never ON (PC 12.5%) and 
non-cleavable probe composed of HPMA copolymer- 
Gly-Gly-Cy5 (P-GG-Cy5) 1.14 mol% (Figure S4B, D). 
The results indicate that our control probes’ increase 
in fluorescence signal was negligible in the presence 
nor in the absence of CTSB. 
 
Figure 3. Active cathepsins labeling of tumor lysates and normal tissues with activity based probe (ABP), GB123. (A) Labeling of active cathepsins in melanoma 
and breast cancer tumor tissues, in comparison with normal tissues (normal skin and normal mammary). Equal amounts of protein were pretreated with 5 µM cathepsins 
inhibitor, GB111-NH2 (+), or DMSO (-) for 45 min in reaction buffer at 37 °C. GB123 (-), 2 µM, was added to all samples for 90 min at 37 °C. Finally, an amount equivalent to 
30 µg of protein was separated by 12.5% SDS-PAGE. GB111-NH2 (+) served as control. Labeled proteases from lysed cells and tissues were visualized by scanning the gel with 
a Typhoon scanner at excitation/emission of 635/670 nm. The fluorescent bands between 20-37 kDa are characteristic of cathepsin enzymes, as was previously demonstrated 
[49, 77]. Loading control for western blot was actin. (B) Graphs show the quantification of cathepsins’ activity relative to actin in normal and tumor tissue lysates. (C) In vivo 
cathepsins expression (red) in breast (4T1) and melanoma (131/4-5B1) tumor sections in comparison with normal tissues, mammary fat pad and skin, respectively. Red indicates 
Cy5 fluorescence of GB123; blue indicates DAPI. (D) Quantification of the signal obtained from tumor tissue slides in comparison with normal tissue slides using ImageJ software. 
Data represent mean ± SD. 
 






Figure 4. Turn-ON properties and kinetics of degradation by CTSB of P-GFLG-Cy5 and PCQ conjugates. (A) Cy5 fluorescence is turned-ON upon incubation 
with CTSB (0.56 U/mL), while in the addition of an inhibitor (CA-074 Me) and in the absence of CTSB, a negligible increase in fluorescence signal was observed. Data represent 
mean ± SD (n = 3). (B) Representative CRI MaestroTM image of P-GFLG-Cy5 probe incubated with CTSB, and controls (no enzyme, and an addition of CTSB inhibitor, CA-074 
Me). (C) Kinetics of the degradation of Turn-ON probes by CTSB. Various concentrations of P-GFLG-Cy5 (red) and PCQ (blue), from 0-60 µM Cy5-eq. concentration, were 
incubated with CTSB 0.2 U/mL at 37 °C for 24 h, and the initial velocity values (v) were analyzed by GraFit 7.0 software. (D) Table of kinetic parameters of the Turn-ON probes 
for CTSB (0.2 U/mL). Data represent mean ± SD (n = 3). 
 
Therefore, we concluded that our Turn-ON 
probes, P-GFLG-Cy5 with 4.06 mol% Cy5 loading, 
and PCQ bearing 1.13 mol% Cy5 and 0.83 mol% 
quencher, exhibited satisfactory quenching properties 
and activation by CTSB. In addition, under 
lysosome-mimicking conditions, pH ~5, the 
conjugates were relatively optically silent in their 
quenched state (i.e., Turn-OFF), and become highly 
fluorescent after enzymatic cleavage of the GFLG 
linker or PGA backbone by CTSB. Other enzymes 
may degrade these polymeric Turn-ON probes. In 
addition to CTSB enzyme, the GFLG linker may also 
be degraded by papain [56], chymotrypsin, which can 
cleave peptide bonds followed by phenylalanine 
(Phe) [57], dipeptidyl aminopeptidase BII (DAP BII), 
which may hydrolyze Gly-Phe substrate [58], and 





orphyromonas gingivalis DPP-7 (PgDPP7), which 
may hydrolyze Leu-Gly substrate [59, 60]. The 
overexpression of cathepsins, such as B, S and L, is 
known to vary between tumor types. Thus, cysteine 
cathepsin-activated probes might be applied in any 
tumor type in which one or more of those proteases 
are overexpressed. In order to compare the different 
activation by different cathepsins that are 
overexpressed and active at the tumor site, we 
incubated our Turn-ON probes with different human 
recombinant (hr) cathepsins—B, L and S. P-GFLG-Cy5 
showed different degrees of degradation by each of 
them (highest degree for CTSL and lowest degree for 
CTSS). The PCQ Turn-ON probe was also degraded 
by all of the hr cathepsins to a different extent, with 
highest degradation by CTSB and lowest by CTSL 
(Figure S5B). In the absence of the enzymes, the 
elevation in the fluorescence intensity was negligible. 
This indicates the stability towards hydrolysis at 
different pH (4.5, 5.5 and 6), which might characterize 
the tumor microenvironment local pH (5.5-7.0) 
[61-63], or the pH in the lysosome (pH 5-5.5) where 
cathepsins are highly active. Nevertheless, the 
microenvironment of many solid tumors is weakly 
acidic (pH 6.5) [64]. To further study the difference in 
site of degradation between the two probes, their 
enzymatic efficiency was evaluated according to 
kinetics constants calculated from the Michaelis- 
Menten equation. The KM of PCQ was slightly higher 
than that of P-GFLG-Cy5 (13.739 vs. 9.869 µM, 
respectively) (Figure 4C), indicating formation of a 
more loosely-bound complex with CTSB than that of 
P-GFLG-Cy5 with the enzyme. Similarly, the turnover 
number of the enzyme, Kcat, was higher for 
P-GFLG-Cy5 than for PCQ (0.218 vs. 0.151 h-1, 
respectively), indicating a more rapid degradation of 
the GFLG linker to release free Cy5 per hour, than the 
degradation of PGA polymeric backbone. Overall, the 
enzymatic efficiency (Kcat/KM) of P-GFLG-Cy5 was 
higher than that of PCQ (22089 vs. 10990 M-1h-1, 
respectively) (Figure 4C-D). 
Inhibition of CTSB activity increases as 
inhibitor concentration rises 
The degradation of GFLG spacer on 
P-GFLG-Cy5 by CTSB was inhibited by the selective 
CTSB inhibitor, CA-074 Me, in a dose-dependent 
manner (Figure S4E-F). As inhibitor concentrations 
increased from 0 to 250 µM, the fluorescence signal 
was decreased to about half of the original signal of 
non-inhibited probe (Figure S4E-F). This indicates a 
selective inhibition of the probe activation that 
possesses a concentration dependence. 
Enhanced in vitro cellular retention and 
Turn-ON properties of the activatable 
conjugates 
Macromolecular carriers can internalize into cells 
through endocytosis. Our probes are designed to be 
degraded by cysteine cathepsins, which cleave the 
linker GFLG in the HPMA copolymer-based probe, to 
release the free fluorophore with its terminal amine. 
The slightly acidic pH ~5 in lysosomes and the 
slightly less acidic endosomes, the main sites of 
enzymatic degradation, may lead to protonation of 
this amine functional group [65]. The fluorophore that 
is positively charged after enzymatic cleavage may 
diffuse in a slower rate through the lysosome 
membrane, leading to its higher retention there [66]. 
This phenomenon is termed the lysosomotropic effect, 
and was recently reported for a low MW 
enzyme-activatable Turn-ON probe [67]. As our 
Turn-ON probes bear densely packed fluorophore 
molecules that generate positively charged 
fluorophores upon degradation by cathepsins (Figure 
S6A), we postulated that in the pH range of lysosomes 
(~5) [68] the Cy5 signal detected in vitro in the cells 
might be higher for our Turn-ON probes, in 
comparison with free Cy5 molecules, at equivalent 
dye concentrations. For the PGA-based probe, we 
postulated that the signal might be higher as it may be 
recognized by γ-glutamyl transpeptidase in the cell 
membrane, resulting in a significant increase in its 
cellular uptake [69]. The fluorescence signal of 
P-GFLG-Cy5 and PCQ probes in live murine 
mammary adenocarcinoma 4T1 and human 
melanoma 131/4-5B1 cells was measured using an 
ImageStream®X Mark II Imaging Flow Cytometer. 
First, we wanted to evaluate whether our Turn-ON 
probes are co-localized with the lysosomes. 4T1 and 
131/4-5B1 cells were stained with a lysosome marker, 
LysoTracker green, and incubated with P-GFLG-Cy5 
and PC Turn-ON probes (respectively) at 37 °C for 2 
h. The live cell imaging results are presented in Figure 
5A. Co-localization analysis of red (Turn-ON probes) 
and green (lysosomes stained by LysoTracker green) 
pixels showed 65.7% and 82.1% co-localization, 
respectively (Figure 5B). Further, after validating that 
our probes went through the lysosome compartment, 
we sought to examine whether the retention time was 
longer in comparison with free Cy5. The cells were 
incubated at 37 °C with P-GFLG-Cy5 and PCQ for 1 h 
and 0.5 h, respectively. For both conjugates, cellular 
uptake and retention were compared with free Cy5 
and untreated cells. 






Figure 5. In vitro co-localization with lysosomes and enhanced retention of PC (left) and P-GFLG-Cy5 (right) Turn-ON probes. (A) Representative 
fluorescence imaging of living 131/4-5B1 melanoma and 4T1 cells treated by LysoTracker® Green (green), a lysosome marker, and Turn-ON probes (red), PC (left) and 
P-GFLG-Cy5 (right), 2 h post incubation. (B) Analysis of imaged living cells showed 82.1% and 65.7% co-localization (dot plot - orange) of the lysosome marker, LysoTracker® 
Green, with PC (left) and P-GFLG-Cy5 (right), respectively. Yellow indicates cells with green (Lysotracker) and red (suitable Turn-ON probe) staining (without co-localization), 
orange indicates co-localization and green indicates non-gated cells.  Similarity signal intensity that represents the co-localization of cells with co-localization is presented in the 
table. (C-D) The cellular uptake of Turn-On probes is higher than that of free Cy5: Internalization of (C) PCQ and (D) P-GFLG-Cy5 probes into live 131/4-5B1 melanoma and 
4T1 murine mammary adenocarcinoma cells. Live cells were monitored 1 h following treatment with free Cy5 and the probes. Untreated cells served as control. Brightfield and 
fluorescence images of (C) PCQ uptake by 131/4-5B1 cells and (D) P-GFLG-Cy5 uptake by 4T1 cells. (E-F) Mean cell fluorescence intensity (blue columns) and percentage of 
positive cells with Cy5 signal (gray columns) upon (E) PCQ uptake and upon (F) P-GFLG-Cy5 uptake. Free Cy5 uptake and untreated cells served as control in both cell lines. 
All fluorescence images were obtained using an ImageStream®X Mark II Imaging Flow Cytometer and analyzed by the supplier software. The data are presented as mean ± SD (n 
= 3). 
 
Then, in order to follow the cellular uptake and 
retention of our probes, the treatments were replaced 
with cell growth medium for 1 h and the live cells 
were monitored. Figure 5C-D shows brightfield and 
fluorescence images of the cells with the probes, Cy5 
or without treatment. The fluorescence intensity from 
the cells treated with our Turn-ON probes was higher 
than that of free Cy5-treated cells (untreated cells 





served as control and the threshold for positive Cy5 
signal was determined according to them). 
Treatments with our polymeric Turn-ON probes 
resulted in a high fluorescence signal of ~4190 AU and 
~12474 AU for P-GFLG-Cy5 and PCQ, respectively. 
Free Cy5 fluorescence signal was significantly lower, 
about ~1450 AU and ~1541 AU, respectively. 
Untreated 4T1 and 131/4-5B1 cells displayed a 
fluorescence signal of about ~260 AU and ~690 AU, 
respectively (Figure 5E-F). In addition, the percentage 
of cells bearing positive Cy5 signal was evaluated. A 
similar trend was observed for P-GFLG-Cy5 and PCQ 
polymeric probes. For the higher fluorescence 
intensity, there was larger number of cells with 
positive Cy5 signal (~80% and ~67% of total cells, 
respectively). For the free Cy5-treated 4T1 and 
131/4-5B1 cells, the percentage of cells with positive 
Cy5 signal out of the total number of cells was lower, 
with ~15% and none, respectively (Figure 5E-F). 
When incubation was prolonged (up to 16 h), there 
was an increase in fluorescence intensity, indicating 
activation of the PCQ system to its Turn-ON state 
(Figure S5C, upper and middle panels, and Figure 
S5D), probably by cathepsins that are highly activated 
in 131/4-5B1 melanoma cells (Figure S5A). In 
addition, we showed the specific inhibition of our 
Turn-ON probe’s activation by cathepsins via 
pre-incubation of 131/4-5B1 living cells with 
cathepsin inhibitor GB111-NH2 prior to treatment 
with PCQ. The fluorescence signal of the cells 1 h 
following treatment removal was almost abolished for 
PCQ + GB111-NH2 in comparison with 131/4-5B1 
cells that were incubated only with PCQ (Figure S5C, 
lower panel). These findings indicate that our probes 
are superior over small molecules as imaging agents. 
They resulted in a higher fluorescence signal upon in 
vitro incubation with different cancer cell lines, and 
presented Turn-ON ability upon cellular incubation. 
In vivo characterization and pharmacokinetics 
(PK) of P-GFLG-Cy5 and PGA-based Turn-ON 
probes 
For further in vivo evaluation of our Turn-ON 
probes, we rationally chose to focus on the 
P-GFLG-Cy5 system 1 and PCQ system 3, which had 
superior characteristics in terms of size and quenching 
capabilities. HPMA copolymer and PCQ sizes 
measured by DLS were ~7.17±1.17 nm and ~152±41 
nm, respectively (Table 1). The P-GFLG-Cy5 size was 
within the suitable size range of imaging agents for 
IGS, i.e., below 10 nm [52]. The PCQ polymeric 
Turn-ON probe with a size within 50-200 nm could 
show better accumulation at the tumor site [29]. In 
order to study our Turn-ON probes’ properties in vivo, 
and to choose the ideal time for image-guided 
surgery, we followed the kinetics and 
tumor-to-background elevation of the Turn-ON 
probes by non-invasive imaging of BALB/c or SCID 
mice inoculated orthotopically with 4T1 mammary 
adenocarcinoma or 131/4-5B1 melanoma cells, 
respectively. In the breast cancer model, 4T1 cells 
were inoculated into the 1st mammary gland of mice 
to generate tumors, while melanoma cells were 
injected intra-dermally to the flank. In order to 
emphasize the importance of Turn-ON probes for in 
vivo imaging, in terms of providing an improved 
tumor-to-background signal, our control probes, 
non-cleavable P-GG-Cy5 and the Always ON PC 0.56 
mol% probes were injected i.v. to BALB/c mice 
bearing 4T1 tumors. Mice were imaged non- 
invasively using a CRI MaestroTM imaging system at 
15 min to 4 h post i.v. administration (Figure S7A-B). 
No elevation in the tumor-to-background signal of the 
non-cleavable and Always ON probes was observed 
over time, and the tumor could not be easily 
distinguished (Figure S7A-C). However, for the 
Turn-ON probe, we found that the tumor-to- 
background ratio was elevated over time, reaching the 
highest signal 4 h post i.v. administration, thus the 
location of tumors could be detected non-invasively 
(Figure S7A-B, lower panel). Macromolecules such as 
polymeric probes may accumulate in the tumor site 
via the EPR effect. In order to exclude that the 
elevation in fluorescence signal occurred only due to 
accumulation of the probe at the tumor site via the 
EPR effect, we injected the probe intratumorally (100 
µM Cy5-eq. concentration, 30 µL) and the fluorescence 
signal from the tumor was measured over 60 min. An 
elevation in the fluorescence signal during that time 
showed that our probe possesses Turn-ON properties 
in vivo, in addition to the accumulation that occurs via 
the EPR effect (Figure S7D). Indeed, the Always ON 
control probe showed that during 4 h post i.v. 
injection, the EPR effect alone does not provide a clear 
detection of the tumor boundaries vs. the healthy 
tissue. Finally, evaluation of the pharmacokinetics 
(PK) of P-GFLG-Cy5 and PC Turn-ON probes in 4T1 
and Ret melanoma tumor-bearing BALB/c and 
C57BL/6J mice resulted in t1/2 of 19 and 22 min, 
respectively. Most of the detectable conjugates were 
excreted from the plasma 3 h post i.v. injection (Figure 
S8B). These results were in good correlation with the 
highest accumulation in the tumor 4 h post i.v. 
administration for P-GFLG-Cy5 Turn-ON probe. In 
addition, the probes were stable in different media 
mimicking physiologic conditions up to 100 h (Figure 
S8A). 
Surgery under P-GFLG-Cy5 guidance 
To test the ability of our Turn-ON probes to 





delineate the tumor boundaries and differentiate 
healthy and cancerous tissue, P-GFLG-Cy5 and PCQ 
were injected i.v. into the tail vein of BALB/c or SCID 
mice inoculated orthotopically with 4T1 mammary 
adenocarcinoma or 131/4-5B1 melanoma cells, 
respectively, as described in the PK studies. Based on 
our PK and tumor-to-background studies (Figure S7 
and Figure S8), we determined the IGS time point to 
be 4 h post i.v. injection of P-GFLG-Cy5 (10 µM, 200 
µL). At this time point, the location of the tumor could 
also be detected non-invasively (Figure 6A). Surgical 
resection of the mammary adenocarcinoma and 
melanoma tumors was performed using the CRI 
MaestroTM imaging system under P-GFLG-Cy5 
fluorescence signal guidance for the breast cancer 
model (Figure 6A), and under PCQ guidance for the 




Figure 6. Surgeries performed under the guidance of P-GFLG-Cy5 (10 µM Cy5-eq. concentration, 200 µL saline) and ProSense® 680 (2 nmol, 150 µL 
PBS). (A) Surgical field representative images of the surgery performed under P-GFLG-Cy5 guidance. IGS was performed 410 min post i.v. injection. Upper panel, brightfield 
images of tumor and tumor bed. Lower panel, the corresponding fluorescence images. Images are representative of 4 mice/group. (B) Comparison of the tumor-to-background 
ratio of the fluorescence signal obtained during IGS of P-GFLG-Cy5 (red) and ProSense® 680 (gray) 4 h (left) and 24 h (right) post i.v. injection (*p= 0.029 and 0.049, respectively, 
two-tailed t-test). Data represent mean ± SD (n=3-5). (C) Comparison between P-GFLG-Cy5 and ProSense® 680 4 h (left panel) and 24 h (right panel) post i.v. injection for 
image-guidance. Left panel: surgical field representative images of P-GFLG-Cy5 (1, 3) vs. ProSense® 680 (2, 4) 4 h post administration. Right panel: surgical field representative 
images of P-GFLG-Cy5 (5, 7) vs. ProSense® 680 (6, 8) 24 h post administration. Fluorescence images were obtained using the CRI MaestroTM imaging system. Filter set: λEx: 635 









The tumor delineated with Cy5 fluorescence 
signal was resected until only a noise signal was 
detected in the surrounding tissue. Furthermore, we 
compared our probe’s performance as an IGS tool to 
three control groups: the first group underwent 
surgery under white light illumination only; the 
second group underwent IGS by the commercially 
available polymeric system ProSense® 680; the third 
group underwent IGS post oral administration of the 
FDA-approved 5-ALA. ProSense® 680, composed of 
PEGylated poly-L-lysine residues bearing self- 
quenched Cy5.5 fluorescent molecules, possesses a 
MW of ~400,000 Da and its ideal imaging time is 
reported to be ~24 h post i.v. administration [33]. 
Hence, it might be less desirable for image-guided 
surgery purposes, since additional hospitalization 
days may be required. To compare between the two 
probes for imaging during surgical procedures, we 
evaluated their kinetics following i.v. injection (Figure 
S10A-B). At 4 h post i.v. administration, ProSense® 
680 tumor-to-background ratio was lower in 
comparison to the P-GFLG-Cy5 (Figure 6B, left 
panel). Moreover, 24 h post i.v. injection, which is the 
suitable Turn-ON time reported and observed for 
ProSense® 680, its tumor-to-background ratio was 
also lower in comparison with P-GFLG-Cy5 imaged at 
the same time point (Figure 6B, right panel). We 
performed image-guided surgeries using both probes, 
at their suitable time points, 24 h and 4 h (Figure 6C). 
Although ProSense® 680 generated a higher signal 
from the tumor compared to the P-GFLG-Cy5, it also 
produced a higher background signal (Figure 
S10A-B). High signal from the tumor may be 
preferable for imaging of enzyme activity at the 
tumor; however, for IGS purposes, the improvement 
of tumor-to-background ratio is highly desirable in 
order to distinguish between healthy and cancerous 
tissue. The third group underwent IGS by 5-ALA 4 h 
post oral administration (0.1 mg/g) (Figure S10C). 
Tumor survival curves demonstrated prolonged 
survival for the mice who underwent IGS by 
P-GFLG-Cy5 guidance in comparison with 5-ALA or 
ProSense® 680 groups (Figure S10D).  
Histological analysis of surgical specimens 
derived from the surgery guided by 
P-GFLG-Cy5 or PCQ Turn-ON probes 
The fluorescent lesions, suspected to be 
cancerous tissues that were resected 4 h and 24 h post 
i.v. injection of P-GFLG-Cy5 and PCQ Turn-ON 
probes’ fluorescence  were imaged ex-vivo by the CRI 
MaestroTM imaging system. Brightfield images and 
Cy5 fluorescence signal detected in the excised 
tumors of breast and melanoma models are presented 
in Figure 7A, C. Next, malignancy analysis of these 
excised 4T1 and 131/4-5B1 tissues by H&E staining 
confirmed that the tissues are indeed cancerous 
lesions (Figure 7A, C, right panel). Furthermore, in 
order to follow P-GFLG-Cy5 and PCQ uptake by cells 
in the tumor area, adjacent sections were fixed with 
PFA, mounted with DAPI and Cy5-positive signal 
was evaluated. As expected, the fluorescence signal, 
resulting from the Turn-ON probes, (red) was 
detected inside the cells in the tumor region (Figure 
7B, D). In addition, we found that the tumor tissue 
showed an increased fluorescence signal in 
comparison with normal mammary tissue (Figure 
S9A-C). As expected, upon i.v. administration of 
P-GFLG-Cy5 to healthy mice, only background signal 
level was observed (between 0.4-2 relative scaled 
counts/s, Figure S9D-E). These results indicate that 
our probes are indeed efficient for specifically labeling 
tumor tissue during surgery. 
Tumor recurrence follow-up after surgical 
resection  
The P-GFLG-Cy5 IGS group and the non-guided 
surgery group (control) were surveilled for tumor 
and/or metastases recurrence, weight change, and 
overall survival for 17 weeks. The group that 
underwent non-guided surgery demonstrated a 
reduced survival rate and had tumor and metastasis 
recurrence earlier then the IGS group (18 and 25 days 
vs. 37 days, respectively; Figure 8C). The first mouse 
that showed a sharp weight loss, at 18 days 
post-surgery, underwent imaging using CRI 
MaestroTM. In order to identify the tumor recurrence 
non-invasively, P-GFLG-Cy5 probe was injected i.v. 
(10 µM Cy5-eq. concentration, 200 µL); four hours 
later, the mouse was anesthetized and imaged. The 
mammary adenocarcinoma tumor was detected 
non-invasively by fluorescence Cy5 signal. Later, we 
validated these findings searching for metastases 
post-mortem. All glowing spots, suspected as 
metastases, and tumor were excised, imaged and 
examined by H&E staining. Two additional mice from 
the non-guided surgery group and the IGS group had 
tumor and metastasis recurrence at days 25 and 37, 
respectively, and were evaluated in the same manner 
for metastasis burden by our Turn-ON probe imaging 
post-mortem. Figure 8A brightfield and fluorescence 
imaging show representative tumor recurrence and 
metastasis spread to the lungs, rib cage and into the 
chest cavity. The tissues were removed, embedded in 
paraffin, sectioned into 5 µm sections and stained 
using H&E to confirm malignancy (Figure 8A, right). 
As expected, the malignant tissues had a higher 
fluorescence signal, resulting from higher uptake, 
retention and Turn-ON ability of the probe (as shown 
in vitro). An average signal of between 1-2.3 relative 





scaled counts/s was observed for the healthy 
surrounding tissues in comparison with 3.1-6.5 
relative scaled counts/s for the metastases within 
them (Figure 8B). The difference between the signal 
obtained from cancerous and healthy tissues was 
found to be statistically significant (p<0.05 between 
the tumor or metastases in the rib cage to the signal 
from healthy lungs). Thus, we demonstrate our probe 
is able to identify small metastases spread among 
healthy tissues, with a clear cut-off differentiation 
from the healthy tissue (dashed black line at ~2.3 
relative scaled counts/s). The difference of the 
average fluorescence signal between the metastases in 
the rib cage to the normal lungs was statistically 
significant (p=0.010), and near statistically significant 
in comparison with normal rib cage bone (p=0.57). In 
the case of lung metastases, there was no statistical 
significance in comparison to normal tissues, which 
can be explained by the necrosis revealed by H&E 
staining (Figure 8A, upper panel). 
 
 
Figure 7. Imaging and histology of resected tumors showing a representative region from the 4T1 (upper panel) and 131/4-5B1 (lower panel) xenografts 
injected with P-GFLG-Cy5 or PCQ (respectively) and excised by their guidance. (A, C) Brightfield and Cy5 imaging of whole excised tumor. Left: for confirmation 
of pathological regions identified using the probe fluorescence, serial 10 µm OCT sections were stained with H&E. P-GFLG-Cy5 (B) and PCQ (D) fluorescence (red) was 
detected inside the cells in the tumor area in both breast and melanoma models, respectively. White scale bars are 50 µm. Black scale bars are 200 µm. Paired H&E staining was 
performed to localize regions of disease. Images of resected tumors are representative of 4 mice. OCT sections are representative of 3 fields-of-view for both H&E and DAPI 
staining. 






Figure 8. Comparison between IGS and non-IGS groups. (A) Tumor recurrence 18 days post standard surgery. Left panel: brightfield. Middle panel: visualization by 
P-GFLG-Cy5 signal (red) in tumor tissue and metastases, using CRI MaestroTM imaging system. Right panel: H&E staining of the tumor and metastases in the different organs 
(lungs, chest cavity and rib cage). Red signal obtained in the tumor and metastases was confirmed in the H&E staining. Black and white scale bars represent 1000 and 100 µm, 
respectively. (B) Uptake of P-GFLG-Cy5 4 h post i.v. injection to healthy vs. cancerous tissues. Fluorescence signal detected from different organs 4 h post i.v. injection of 
P-GFLG-Cy5 (10 µM, 200 µL). The difference between signal from tumor and rib cage metastases to the normal lung was statistically significant (one-way ANOVA). (C) 
Kaplan–Meier survival curve. Tumor-free survival after surgery vs. time (days) for 4T1 mammary adenocarcinoma mice (n = 4 for P-GFLG-Cy5 guidance, n = 4 for non-guided 
surgery) showing improved long-term tumor-free survival with P-GFLG-Cy5 guidance (red) compared to non-guided surgery (black), performed under white light illumination 
only. Images are representative of 3 mice with tumor and metastases recurrence. H&E images are representative of 3 fields-of-view for each section. 






There is an unmet need for advanced technology 
and tools to better delineate tumor boundaries in 
real-time during surgery for complete tumor excision. 
This may reduce the risk for tumor recurrence, 
repeated surgeries and improve post-surgery quality 
of life due to minimal harm to healthy tissue. In 
addition, it may hopefully lead to improved patient 
survival rates. Fluorescence imaging is a highly 
beneficial technique for real-time assessment of tumor 
boundaries during surgical procedures and holds 
many advantages. Apart from the relatively low cost 
of the fluorescent contrast agent, it is considered to be 
safe for the patient and for the medical team, 
generates high signal upon activation, and can be 
designed to be activated through certain molecular 
pathways. Thus, it can be tailored to the patient 
according to their specific biomarkers in a 
personalized manner. Furthermore, use of 
fluorophores in the far-red range or above leads to an 
improved depth of penetration and reduced 
scattering of light, thus allowing visualization of 
cancer cells up to 0.5 cm depth [17]. From the 
surgeon’s point of view, with this beneficial depth 
range, the cancerous tissue in the surgical field would 
not be apparent except by looking through special 
goggles or at a screen. Thus, the surgeons could 
decide how much tumor to remove both by white 
light and palpitation as they are used to, while 
validating that no cancer cells are missed in real time 
by looking at the fluorescence signal on a screen or 
special goggles.  
In this study, we report the design, synthesis and 
characterization of three novel polymeric, 
cathepsin-activatable, Turn-ON probes (Figure 1A-B). 
Using two different polymeric systems with diverse 
Turn-ON mechanisms, we sought to study how the 
difference in the site of degradation by cathepsins 
(polymeric backbone vs. substrate linker) and the size 
alter their in vitro and in vivo performance. We showed 
in this study that the size may influence the time to 
start the IGS post i.v. injection in vivo, which was 4 h 
vs. 24 h when using the larger particle. In addition, we 
compared the first generation polymeric “smart” 
probe [33], now commercially available as ProSense® 
680 (PerkinElmer Inc.), to our P-GFLG-Cy5 probe. As 
expected, the commercial agent displayed prolonged 
accumulation and a slower Turn-ON time in the 
tumor of ~24 h post i.v. administration (Figure S10A). 
This prolonged time might be attributed to the larger 
MW of ProSense® 680, reported to be ~400,000 Da. 
This might be less preferable for surgical resection 
applications, from an economic point of view, 
requiring unnecessary in-patient days. The 
P-GFLG-Cy5 Turn-ON probe generated maximal 
NIRF signal ~4 h post i.v. administration. In addition, 
its hydrodynamic diameter of ~7 nm, which is below 
10 nm, is within the suitable size range of probes used 
for IGS [52] that is reflected by the latest agents 
evaluated in clinical trials [40, 70]. This size is large 
enough to accumulate in the tumor and maintain 
there during the operation and imaging, and small 
enough to be cleared from the circulation. Although a 
probe’s macromolecule size and physical properties 
mainly affect the time it takes to accumulate in the 
tumor, it should be taken into consideration that the 
enzymatic catalytic efficiency (Kcat/KM) of CTSB to the 
Turn-ON probes may also affect their Turn-ON 
fluorescence signal. Thus, the difference in enzymatic 
efficiency of our Turn-ON probes was evaluated in 
vitro. The calculated catalytic efficiency was higher for 
P-GFLG-Cy5 (Figure 4C-D), indicating that CTSB and 
GFLG form a stronger bound complex, with faster 
turnover (degradation) rate compared to the PCQ 
probe. This finding was additional to its faster in vivo 
tumor accumulation in comparison with PCQ, 
presumably due to its lower hydrodynamic diameter 
(Table 1). Alternative fluorescently activatable 
imaging probes for image-guided surgery or for 
tumor imaging that are based on FRET have been 
recently published. The FRET pair composed of two 
NIR dyes, whose fluorescence signal changes upon 
activation, thus the activation is detected in a second 
step by ratiometric image analysis [71, 72]. While 
these reports demand further image analysis, which is 
time-consuming and also currently unavailable for 
real-time procedures, our system showed a Turn-ON 
capacity of about 3-fold change, using a simpler 
system bearing one kind of dye, which is paramount 
for clinical translation. Our probes were designed to 
possess optimal dye loading for enzymatic cleavage 
and Turn-ON ability (Figure 2C and Figure 4A). In 
addition, our diagnostic system is non-targeted, and 
the increase in the fluorescence signal in the tumor 
site results from the Turn-ON activation (Figure 
4A-B), the EPR effect, and the improved signal from 
cancerous cells altogether (Figure 5A-D). The 
addition of a targeting moiety adds complexity to the 
system in terms of synthesis, characterization and 
reproducibility, which hamper translation to the clinic 
[73]. Moreover, the advantages of targeting agents on 
macromolecules are still debatable, and reports show 
similar delivery for both targeted and non-targeted 
macromolecules. [74-76]. 
We followed the probes’ performance as guiding 
tools during surgeries of two orthotopic cancer 
models: 4T1 murine mammary adenocarcinoma and 
131/4-5B1 human melanoma. These two cancer types 
are known to metastasize to the brain; thus, early 





detection and highly efficient tumor resection are 
highly important to minimize chances of leaving 
residual cancer cells post operation. First, we 
validated that our desired models of cancer cell lines 
overexpress cathepsins, which should also be done 
clinically to verify patient’s biomarkers, and then, to 
tailor the relevant and specific biomarker-activatable 
probe that will be turned-ON and report upon the 
pathological spots during medical procedures. We 
expected to gain an improved in vivo accumulation in 
the tumor site due to the EPR effect and Turn-ON 
ability of our probe that resulted from the tumoral 
cathepsins overexpression. Thus, in addition to the 
EPR effect and cathepsins activation, we found 
improved cellular uptake and retention when 
attaching the dye and/or quencher molecules to these 
polymeric systems (Figure 5C-F). The improved 
uptake of the conjugates compared to that of free Cy5 
can be attributed to the fact that free Cy5 has a 
negative charge, thus it would be repelled by the 
negatively charged cell membrane. In addition, signal 
retention might improve as fluorophores or low MW 
molecules become positively-charged post enzymatic 
cleavage in the acidic lysosomal compartment, as was 
previously described as the lysosomotropic effect [67]. 
Taken together, this can result in the improved 
tumor-to-background signal that was observed in vivo 
(Figure S7A-C, lower panel). The probes marked the 
tumor boundaries of orthotopic in vivo models of 
mammary and melanoma tumors. To translate 
Turn-ON probes as tumor boundary markers for 
real-time surgical resection for clinical use, validation 
using histological sections is required. This can also 
assist pathologists’ decision-making during histology 
sections examination using a fluorescence microscope, 
with the benefits of high sensitivity and double/triple 
staining of single slides. Although the PCQ had a 
slightly better quenching effect than P-GFLG-Cy5, we 
showed that for a higher loading of Cy5 on Never ON 
PC probe 12 mol% there was no degradation by CTSB, 
probably due to steric hindrance (Figure S4). Hence, 
to avoid steric hindrance we aimed for a lower 
loading in the FRET system (dye + quencher). We 
chose P-GFLG-Cy5 from two main reasons. First, the 
P-GFLG-Cy5 delineated the tumor boundaries 4 h 
post i.v. injection, while PCQ and ProSense® 680 
required 24 h. The shorter duration is beneficial for 
surgery purposes, such as saving unnecessary 
in-patient days. Second, we preferred, for 
translational reasons, to use a simpler and effective 
system that does not require a third component (the 
quencher). Our study showed that the group that 
underwent surgery using P-GFLG-Cy5 guidance 
demonstrated longer survival rates than the control 
groups that underwent either non-guided surgery 
(Figure 8C), or surgery guided by ProSense® 680 or 
5-ALA (Figure S10D). Furthermore, by i.v. 
administration of our Turn-ON probe, we could 
detect the fluorescence signal in tumors and small 
metastases in different organs such as the rib-cage, 
chest cavity, lungs (Figure 8A-C) and brain (Figure 
S11). The malignancy of the excised suspected lesions 
was further confirmed by H&E staining to be 
cancerous. To conclude, we demonstrate the novel use 
and great clinical potential of the polymeric Turn-ON 
probes as a tool to aid surgeons in real-time during 
surgery for complete resection of cancerous tissue. 
This may reduce harm to surrounding healthy tissue, 
and increase the precision of complete resection. 
Taken together, it may potentially achieve the 
ultimate goal of improving patient survival rates and 
quality of life post-surgery.  
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4',6-diamidino-2-phenylindole; DCC: N,N'-dicyclo-
hexylcarbodiimide; DCM: dichloromethane; DEA: 
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N-(2-hydroxypropyl)methacrylamide GFLG: Gly- 
Phe-Leu-Gly: GG: Gly-Gly; HPLC: high-pressure 
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Poly-L-α-glutamic acid; PDI: polydispersity; Q: dark 
quencher; Q-NHBoc: aminated dark quencher 
protected with Boc; SLN: sentinel lymph nodes; TFA: 
trifluoroacetic acid; THF: tetrahydrofuran; Wt%: 
weight percent. 
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